SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?


To: Icebrg who wrote (1369)2/18/2005 8:12:09 AM
From: rkrw  Read Replies (1) | Respond to of 1834
 
One big mistake in the article is that nbix/pfe deal isn't a profit share, but a straight royalty and a high one at that. If icos was earning royalties at that same rate I suspect it would be profitable and trading significantly higher than 23.

sepr isn't getting much credit for its pipeline either. gsk calls a once a day beta a holy grail for copd and there is sepr with one late in phase III.